Article
Pharmacokinetics of daclatasvir in Egyptian adolescents with genotype-4 HCV infection.
Antiviral therapy - 1 Jan 2020
Al-Nahari Mogeb M, Abbassi Maggie M, Ebeid Fatma Se, Hassany Mohamed, El-Sayed Manal H, Farid Samar F
Abstract excerpt
BACKGROUND: Daclatasvir has potent antiviral activity against HCV infection when used in combination with sofosbuvir, however, its pharmacokinetics have not been described in adolescents. The aim is to determine the pharmacokinetic parameters of daclatasvir in adolescents, and to develop a population pharmacokinetic (PopPK) model. METHODS: Seventeen adolescent patients with genotype-4 chronic HCV infection...
Read the complete abstract on PubMedTopics
Share this publication in a Topic to start or enrich a Post.